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A b s t r a c t  
The aim of the present work was in vitro and in vivo evaluation of mucoadhesive tablets of lafutidine 
to prolong the gastric residence time after oral administration. Formulations were prepared using 33 
full factorial designs to explore the effects of Gum Kondagogu, Gum Olibanum and Guar Gum (as 
independent variables) on mucoadhesive strength, drug release and Ex vivo residence time (as 
dependent variables) was studied and published in the earlier research paper.  
In this investigation the formulated mucoadhesive tablets which was optimized through         in vitro 
studies is selected and performed the in vivo studies on Human volunteers. The drug-polymer 
interaction was also studied by conducting FTIR and DSC tests. The in vitro release kinetics studies 
reveal that all formulations fits well with Zero order, followed by Korsmeyer-Peppas, Higuchi and the 
mechanism of drug release is erosion. After analysis of different evaluation parameters and drug 
release kinetics, formulation code F22 was selected as a promising formulation for delivery of 
lafutidine as a mucoadhesive Gastroretentive tablet with best mucoadhesive strength and 99.54% 
drug release at 12th hour. Radiological evidences suggest that, a formulated tablet was well adhered 
for >10 h in human stomach. The bioavailability studies of F22 containing lafutidine was carried out 
which exhibited increased pharmacokinetic parameters of Cmax (268μ1.26), Tmax (1.30μ1.23 h) 
and AUC0-t (1048μ16.42) as compared to marketed formulations which indicates improved 
bioavailability of formulations. 
Keywords: Lafutidine, Mucoadhesive, Radiographic studies, In vivo bioavailability studies. 
Introduction 
Oral administration is the most convenient, widely utilized, and 
preferred route of drug delivery for systemic action. However, when 
administered orally, many therapeutic agents are subjected to 
extensive presystemic elimination by gastrointestinal degradation 
and or first pass hepatic metabolism, as a result of which low 
systemic bioavailability and shorter duration of therapeutic activity. 
Much attention has been focused, recently on targeting a drug 
delivery system to a particular region of the body for extended 
period of drug release, not only for local targeting of drugs but also 
for the better control of systemic delivery [1]  
Naturally occurring polymers, being biocompatible and 
biodegradable, are currently extensively researched for the 
development of novel drug delivery systems. There are number of 
drugs like domperidone, ranitidne, theophylline those have narrow 
absorption window from upper GIT i.e. stomach. Due to short 
gastric resident time less than 3 hr these drug reaches the non 
absorbing distal parts of intestine. Therefore main challenge is to 
prolong the resident time of drug in stomach. Gastro retentive drug 
delivery techniques are primarily controlled release drug delivery 
systems, which gets retained in the stomach for longer period of 
time, thus helping in absorption of drug for the intended duration of 
time. It helps to improves bioavailability, reduces drug wastage, 
improve solubility of drugs that are less soluble at high pH 
environment (e.g. weakly basic drugs like domperidone, 
papaverine) [2]. 
Lafutidine,(μ)-2-(furfurylsulfinyl)-N-(4-[4-[piperidinomethyl]-2-
pyridyl]oxy-(Z)-2-butenyl) acetamide is a newly developed 
2 nd generation histamine H2-receptor antagonist. It is used in the 
treatment of gastric ulcers, duodenal ulcers, and gastric mucosal 
lesions associated with acute gastritis and acute exacerbation of 
chronic gastritis. It is absorbed in the stomach, reaches gastric cells 
via the systemic circulation, and rapidly binds to gastric cell 
histamine H2 receptors, resulting in immediate inhibition of gastric 
acid secretion.  Lafutidine has been shown to increase the gastric 
mucosal blood flow and gastric mucus secretion also accelerates 
epithelial restitution in rats. Lafutidine has a receptor binding 
affinity, which is 2-80 times higher than famotidine, ranitidine and 
cimetidine [3].  
 
Materials and Methods 
Materials 
 
The Lafutidine was obtained as a gift sample from splendid 
laboratories, Pune. Gum Kondagogu, Gum Olibanum and Guar 
Gum were obtained from Girijan Co-operative corp. Ltd, 
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Hyderabad.   PVP-K30 was gifted from MSN Labs Ltd, Hyderabad. 
All other chemicals used were of analytical grade. 
 
Preparation of Mucoadhesive Tablets 
Wet Granulation Method 
Mucoadhesive tablets of Lafutidine were prepared by wet 
granulation technique using different concentrations of Gum 
Kondagagu, Gum olibanum and Guar gum. All the ingredients were 
passed through sieve no 85# and were mixed uniformly. 
Granulation was carried out with sufficient quantity of binder 
solution (PVP K 30 - 5% in isopropyl alcohol). Wet mass was 
passed through sieve no 12# and dried at 45-55 0C for 1 hr. Dried 
granules were sized by sieve no.18#. Add magnesium stearate and 
talc. Granules obtained were compressed with 9 mm flat punch 
(Cadmach, Ahmedabad, India) [4].  
 
 
The formulations are made by using design of 
experiment method (factorial designs) 
 Study type: Response surface 
Design type: Central Composite 
Design mode: Quadratic 
 
Table No: 1 Design Summary Of Formulation By Natural Polymers 
F.NO LAFUTIDINE 
(mg) 
GK 
(mg) 
GO 
(mg) 
GG
(mg) 
MCC
(mg) 
PVP
K-30 
(mg) 
TALC
(mg) 
MAGNESIUM 
STEARATE 
(mg) 
TOTAL 
WEIGHT 
(mg) 
F1 10 10 10 10 140 12 4 4 200
F2 10 30 10 10 120 12 4 4 200
F3 10 10 30 10 130 12 4 4 200
F4 10 30 30 10 100 12 4 4 200
F5 10 10 20 10 130 12 4 4 200
F6 10 30 20 10 110 12 4 4 200
F7 10 20 10 10 130 12 4 4 200
F8 10 20 30 10 110 12 4 4 200
F9 10 20 20 10 120 12 4 4 200
F10 10 10 10 40 110 12 4 4 200
F11 10 30 10 40 90 12 4 4 200
F12 10 10 30 40 90 12 4 4 200
F13 10 30 30 40 70 12 4 4 200
F14 10 10 20 40 100 12 4 4 200
F15 10 30 20 40 80 12 4 4 200
F16 10 20 10 40 100 12 4 4 200
F17 10 20 30 40 80 12 4 4 200
F18 10 20 20 40 90 12 4 4 200
F19 10 10 10 60 90 12 4 4 200
F20 10 30 10 60 70 12 4 4 200
F21 10 10 30 60 70 12 4 4 200
F22 10 30 30 60 50 12 4 4 200
F23 10 10 20 60 80 12 4 4 200
F24 10 30 20 60 60 12 4 4 200
F25 10 20 10 60 80 12 4 4 200
F26 10 20 30 60 60 12 4 4 200
F27 10 20 20 60 70 12 4 4 200
GK: Gum Kondagogu                     GO: Gum Olibanum                             GG: Guar Gum. 
                  Mcc: Micro Crystalline Cellulose                                                                            PVP K-30: Polyvinyl Pyrolidone K-30. 
 
In-vitro dissolution studies The USP dissolution test apparatus (apparatus II paddle type) was 
used to study the drug release from the tablets. The dissolution 
medium was 900 ml of 0.1N HCl buffer pH 1.2. The release was 
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performed at 37 μ 0.5ĈC, with a rotation speed of 100 rpm. 5ml 
samples were withdrawn at predetermined time intervals and 
replaced with fresh medium. The samples were filtered through 
whatmann filter paper and analyzed after appropriate dilution by UV 
spectrophotometer at 220 nm and drug release was determined 
from standard curve [5] 
 
Dissolution Parameters 
Dissolution medium:  900 ml of 0.1 N HCl buffer with pH 1.2 
RPM: 100 
Temp: 37 μ 0.5Ĉc 
Sample volume withdrawn: 5ml sample 
λ max  : 220 nm 
Time interval: 0, 1, 2, 3, 4, 6, 8, 10 & 12h.  
 
Drug Excipient Compatibility Studies 
 
The drug excipient compatibility studies were carried out by Fourier 
transform infrared   spectroscopy (FTIR), DSC & SEM.  
 
 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra for pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The samples were dispersed in KBr 
and compressed into disc/pellet by application of pressure. The 
pellets were placed in the light path for recording the IR spectra. 
The scanning range was 400-4000 cm-1 and the resolution was 1 
cm-1. 
 
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. Samples 
were accurately weighed and heated in sealed aluminium pans at a 
rate of 10ĈC/ min between 25 and 350ĈC temperature rang under 
nitrogen atmosphere. Empty aluminium pan was used as a 
reference.[6] 
 
SEM studies 
The surface and shape characteristics of Tablets were determined 
by scanning electron microscopy (SEM) (HITACHI, S-3700N). 
Photographs were taken and recorded at suitable magnification. 
 
Stability studies 
The stability study of the optimized formulation was carried out 
under different conditions according to ICH guidelines. The 
optimized tablets were stored in a stability chamber for stability 
studies (REMI make). Accelerated Stability studies were carried out 
at 40 0C / 75 % RH for the best formulations for 6 months. The 
tablets were characterized for hardness, mucoadhesive strength 
and cumulative % drug released during the stability study period.[6] 
 
In-vivo bioavailability studies 
In vivo study protocol 
Twelve healthy male subjects with a mean age of 28.83μ3.60 years 
(ranging from 24 to 34 years), mean weight 69.33μ7.61Kg (ranging 
from 61 to 79 Kg) and a mean height of 173.17 μ 10.46cm (ranging 
from 157 to 182cm) participated in this study. Informed and signed 
consent and approval of the Human Ethical Committee were 
obtained. The volunteers were judged healthy on the basis of their 
previous medical history, physical examination and routine 
laboratory tests. None of the subjects used alcohol or tobacco. All 
subjects were free from drugs 15 days before and during the study. 
They were randomly divided into 2 groups of 6 subjects each. The 
subjects were fasted over night at least 10h prior to dose. After 
collecting the zero hour blood sample (blank). A standardized high 
fat-breakfast approximately 900KCal was given in the morning half-
an-hour before administration. Group A received Formulated 
lafutidine mucoadhesive tablets and group B received commercial 
formulation with 200ml of water. All the subjects were given a glass 
of water for every 2h (approximately 200ml). Standardized lunch, 
snacks and dinner was provided to all the subjects respectively at 
4, 8 and 12h after the administration of formulations. Blood 
samples (2ml) were collected by the intravenous route using 
heparinized disposable syringes at the following times: 0.5, 1, 1.5, 
2, 2.5, 3, 4, 6, 8, 12, 16, 20 and 24h. The blood samples were 
collected in vacutainers containing EDTA as anticoagulant and 
immediately centrifuged at 3000rpm for 15min. The separated 
plasma samples were stored at -200 C until analyzed [7] . 
 
Determination of lafutidine in Human plasma by HPLC 
method  
Determination of lafutidine using internal standard Domperidone by 
high performance liquid chromatography with a RP-C18 
chromatographic column, Phenomenex Kinetex (150 mm ï 4.6 mm 
i.d) as stationary phase and the mobile phase consist of 0.02M 
Potassium dihydrogen phosphate: Acetonitrile: Methanol in a ratio 
of 50:35:15v/v/v at the flow rate of 1ml/min. and the wavelength 
detection was done at 285nm. The retention time for Lafutidine and 
Domperidone were found to be 4.3 and 5.6 min, respectively [7]. 
 
Preparation of Plasma Samples for HPLC Analysis  
Human plasma (0.5ml) was prepared for chromatography by 
precipitating proteins with 2.5ml of ice-cold absolute ethanol for 
each 0.5ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was resuspended with 
1 ml of acetonitrile by vortexing for 1min. After centrifugation (5000 
ă 6000 rpm for 10 min), the acetonitrile was added to the ethanol 
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and the organic mixture was taken to near dryness by a steam of 
nitrogen at room temperature. Samples were reconstituted in 
200μ1 of 50% of acetonitrile and 50% 0.1% ortho phosphoric acid 
was injected for HPLC analysis.  
 
Pharmacokinetic Analysis 
The pharmacokinetic parameters, peak plasma concentrations 
(Cmax) and time to reach peak concentration (tmax) were directly 
obtained from concentration time data. In the present study, AUC0-t 
refers to the AUC from 0 to 24h, which was determined by linear 
trapezoidal rule and AUC0-α refers to the AUC from time at zero 
hours to infinity. The AUC0-α was calculated using the formula 
AUC0-t + [Clast/K] where C last is the concentration in ng/ml at the 
last time point and K is the elimination rate constant. Various 
pharmacokinetic parameters like area under the curve [AUC], 
elimination half life (tó). Volume of distribution (Vd), total clearance 
(ClT) and mean residence time for each subject using a non 
compartmental pharmacokinetic program. The pharmacokinetic 
parameters were performed by a non compartmental analysis using 
Win Nonlin 3.3® pharmacokinetic software (Pharsight Mountain 
View, CA USA). All values are expressed as the mean μSD. 
Statistical analysis was performed with Graph Pad InStat software 
(version 3.00, Graph Pad Software, San Diego, CA, USA) using 
one-way analysis of variance (ANOVA) followed by TukeyăKramer 
multiple comparison test. Difference with p<0.05 was considered 
statistically significant [8]. 
 
In-Vivo radiographic studies 
The bio-study protocol for radiographic studies was approved by 
Institutional Human Ethics Committee, No: 
IHEC/VGOPC/053/2015. From the formulations 25mg and 40mg of 
the drug was changed with barium sulfate to make them x-ray 
opaque. The subjects were given these tablets with breakfast. The 
volunteers were given 200 mL of water at zero time, to ensure the 
absence of radio-opaque material in the stomach. X-ray images 
were taken using (Genesis 50, Josef Bets chart AG, Brunnen, 
Switzerland) in standing position after 0.5, 2, 4 and 10 hrs post-
administration of tablets. From the X-ray films gastric residence 
and position was interpreted. 
 
Results & Discussion 
 
Physico-chemical parameters of lafutidine 
mucoadhesive tablets 
The prepared tablets were evaluated for different physico-chemical 
properties and the results are found to be within the 
pharmacopoeial limits. 
 
Kinetic modeling of drug release 
To explore the mechanism of drug release from Mucoadhesive 
tablets, various kinetic models like zero order, first order, Higuchi 
and Korsmeyer-Peppas equations were applied to the different 
formulations. The release kinetics of best formulation (F22) was 
shown in Table 4. From the data it was concluded that the 
Table: 2 Release kinetics of optimized formulation of Lafutidine mucoadhesive tablets: 
Formulation Code 
Zero Order First Order Higuchi Korsmeyer-Peppas 
R2 K R2 K R2 K R2 N 
F22 0.994 8.020 0.842 0.119 0.946 29.51 0.628 2.155
 
From the above results it is apparent that the regression coefficient 
value closer to unity in case of zero order plot i.e.0.994 indicates 
that the drug release follows a zero order mechanism Table No:2. 
This data indicates a lesser amount of linearity when plotted by the 
first order equation. Hence it can be concluded that the major 
mechanism of drug release follows zero order kinetics. 
Further, the translation of the data from the dissolution studies 
suggested possibility of understanding the mechanism of drug 
release by configuring the data in to various mathematical modeling 
such as Higuchi and Korsmeyer-Peppas plots. The mass transfer 
with respect to square root of the time has been plotted, revealed a 
linear graph with regression value close to one i.e. 0.946 starting 
that the release from the matrix was through diffusion. Further the n 
value obtained from the Korsmeyer-Peppas plots i.e. 0.628 suggest 
that the drug release from tablets was anomalous Non fickian 
diffusion. 
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Figure: 4 DSC thermogram of lafutidine 
 
 
 
 
 
 
 
Figure: 5 DSC Thermogram of optimized tablets F22 
DSC was used to detect interaction between Lafutidine and 
excipients. The thermogram of Lafutidine exhibited a sharp 
endotherm melting point at 96 0C. The thermogram of microsphere 
loaded with Lafutidine exhibited a sharp endotherm melting point at 
99 0C DSC results  of formulated Lafutidine is slightly higher that is 
96 0C .The DSC thermogram of microsphere loaded with Lafutidine 
retained properties of Lafutidine, as well as polymer properties. 
There is no considerable change observed in melting endotherm of 
drug in optimized formulation. It indicates that there is no 
interaction between drug & excipients used in the formulation. 
 
 
 
 
 
 
  
 
 
 
 Figure: 6 Scanning Electron Microscopy of lafutidine mucoadhesive 
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    Figure: 7 Scanning Electron Microscopy of lafutidine mucoadhesive 
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                                                                  Figure: 8 Scanning Electron Microscopy of lafutidine mucoadhesive tablets 
 
Radiographic studies 
Intragastric behavior of lafutidine mucoadhesive tablets 
The radiographic images were taken at different periods post 
administration of the barium sulfate-loaded tablet in three human 
volunteers. It is clear that the tablet appears more or less at the 
same position for the initial 4 h. This could be related to its floating 
ability. Later on, the tablet was slightly moved downwards, yet, 
remained within the stomach till the end of 10 h. The increased 
gastric residence time favours increase in the bioavailability of 
drugs. 
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                    Figure: 9 Radiographic Images of a BaSo4 loaded Lafutidine mucoadhesive tablet (F 22) in the stomach  
 
 
 
 
 
 
 
 
          
 
   Figure: 10 Percentage drug release of Lafutidine formulations F22 & Innovator 
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       Figure: 12 Plasma concentrations at different time intervals for lafutidine optimized formulation and Marketed Product 
 
Table: 4 Comparison of pharmacokinetic parameters of lafutidine optimized formulation and Marketed Product 
Parameters Lafutidine Optimized formulation 
(F22) 
Marketed Product 
Cmax(ng/ml) 268μ31.26 206μ29.52 
AUC0-t(ng. h/ml) 1048μ16.42 862μ24.26 
AUC0-¥ (ng. h/ml) 1225μ38.54 1004μ35.14 
Tmax (h) 2.30μ1.23 3.78μ0.29 
t1/2 (h) 2.21 μ 0.91 2.96 μ 0.88 
Kel (h-1) 2.807 μ 0.11 2.189 μ 0.33 
 
Bioavailability parameters 
Mean plasma concentration profiles of prepared lafutidine 
optimized formulation and marketed product are presented in 
Figure.10 Lafutidine optimized formulation exhibited as sustained 
release in vivo when compared with marketed tablet. All the 
pharmacokinetics parameters displayed in Table.4 in this study in 
human subjects, prolonged drug absorption was achieved with the 
test formulation. The average peak concentration of the test 
formulation was significantly higher than that of the reference 
Gudas et al. International Journal of Drug Delivery 8 (2) 50-59 [2016] 
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(268μ31.26 ng/ml for the test formulation versus 206μ29.52 ng/ml 
for the reference). In order to estimate the amount of drug 
absorbed from the test formulation, the relative bioavailability was 
calculated from the AUC of the reference and test formulations 
(1004μ35.14 ng.h/ml for the reference product versus 1225μ38.54 
ng.h/ml for the test formulation). The results indicated that the test 
formulation could increase the bioavailability of Lafutidine in 
humans effectively. In this study, the Lafutidine mucoadhesive 
tablet produce higher bioavailability than that of a marketed 
product, this overall increase in bioavailability and increased gastric 
residence time due to mucoadhesion of tablet in the stomach 
region for 10 h [9]. 
 
Conclusion 
Lafutidine mucoadhesive oral tablets could be formulated using the 
drug, Gum Kondagogu, Gum Olibanum and Guar Gum with 
different proportions using 33 full factorial designs. It can be seen 
that there is a synergistic effect when polymers are used in 
combinations. The in vitro release kinetics studies reveal that all 
formulations fits well with Zero order, followed by Korsmeyer-
Peppas, Higuchi and the mechanism of drug release is erosion.  
From the formulations F1-F27 the formulation F 22 was selected as 
optimized formulation because it showed maximum release and the 
other properties such as swelling index was also low, 
mucoadhesion force shown  good and the Post and pre 
compression parameters were found to be within the 
Pharmacopeial limits. 
Radiological evidences suggest that, a formulated tablet was well 
adhered for >10 h in human stomach. The bioavailability studies of 
F 22 containing lafutidine was carried out which exhibited increased 
pharmacokinetic parameters of Cmax, Tmax and AUC as 
compared to marketed formulations which indicates improved 
bioavailability of formulations. 
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